Year: 2023

Novo Nordisk’s sales increased by 29% in Danish kroner and by 33% at constant exchange rates to DKK 166.4 billion in the first nine months of 2023

Written by Customer Service on November 2, 2023. Posted in Public Companies.

Bagsværd 2 November 2023 – Financial report for the period 1 January 2023 to 30 September 2023 Operating profit increased by 31% in Danish kroner and by 37% at constant exchange rates (CER) to DKK 75.8 billion. Sales in North America Operations increased by 46% in Danish kroner (49% at CER). Sales in International Operations increased by 12% in Danish kroner (17% at CER). Sales within Diabetes and Obesity care increased by 36% in Danish kroner to DKK 153.8 billion (40% at CER), mainly driven by GLP-1 diabetes sales growth of 45% in Danish kroner (49% at CER) and Obesity care growing by 167% in Danish Kroner to DKK 30.4 billion (174% at CER). Rare disease sales...

Netcompany – Interim report for the nine months ended 30 September 2023

Written by Customer Service on November 2, 2023. Posted in Public Companies.

Netcompany grew topline by 9.2% in Q3 driven by strong performance internationally. Cash flow improved sequentially from Q2 as expected. Company AnnouncementNo. 12/20232 November 2023 Summary In Q3 2023, Netcompany grew revenue to DKK 1,461.7m – equal to 8.4% growth compared to Q3 2022 and 9.2% in constant currencies. Adjusted EBITDA was DKK 219.9m compared to DKK 308.9m in Q3 2022. Adjusted EBITDA margin was 15% in Q3 2023 compared to 22.9% in Q3 2022. The average number of full time employees grew from 7,039 in Q3 2022 to 7,760 in Q3 2023. Free cash flow was DKK 100.4m compared to DKK 221.5m in Q3 2022. “In Q3, we grew revenue by 9.2% – once again driven by strong results in the international operation of the Group. The prolonged decision processes experienced in Q2 in the Danish private segment were extended into Q3 too, which...

EfTEN United Property Fund unaudited financial results for the 9 months and 3rd quarter of 2023

Written by Customer Service on November 2, 2023. Posted in Earnings Releases And Operating Results.

EfTEN United Property Fund earned a net loss of 16 thousand euros in the 3rd quarter of 2023, and 87 thousand euros in 9 months of 2023. The loss was due to the market value change in listed EfTEN Real Estate Funs AS shares, which fell by almost 6% during the Q3. In a situation where the balance sheet net asset value of the EfTEN Real Estate Fund AS shares would be used as a basis for determining the net value of the EfTEN United Property Fund, the fund would have earned 330 thousand euros of net profit in the 3rd quarter. Due to the low level of financial leverage and relatively large uninvested capital, the increase in interest rates has had a smaller negative impact on the EfTEN United Property Fund compared to many other European and Baltic investment property funds. With the persistent weak economic activity in the Eurozone, business...

Compagnie Financière Tradition: Growth in activity for the first nine months of 2023 with adjusted revenue of CHF 793.5m, up 8.8%

Written by Customer Service on November 2, 2023. Posted in Public Companies.

Ad hoc announcement pursuant to Article 53 of the Six ExchangeRegulation Listing Rules Lausanne, 2 November 2023Growth in activity for the first nine months of 2023 with adjusted revenue of CHF 793.5m, up 8.8% at constant exchange rates Compagnie Financière Tradition activity grew over the first nine months of the year with reported consolidated revenue of CHF 738.3m compared with CHF 716.3m in the same period in 2022, up 9.7% at constant exchange rates (an increase of 3.1% at current exchange rates). The Group’s consolidated adjusted1) revenue was CHF 793.5m against CHF 777.7m in 2022, up 8.8% at constant exchange rates which is the result of an increase of 8.7% in interdealer broking business (IDB) and 10.4% in the forex trading business for retail investors in Japan (Non-IDB). The strong international footprint...

Inbank issued 12 million euros worth of new shares

Written by Customer Service on November 2, 2023. Posted in Public Companies.

AS Inbank issued 601,957 new shares through private placement to existing shareholders, employees and new investors. The subscription period ended on 30 October 2023 and the Supervisory Board of Inbank decided to issue a total of 12,039,140 million euros worth of new shares to 71 investors. The price of one offered share was 20 euros, of which 0.10 euros was the nominal value and 19.90 euros was the share premium. As a result of the issue of new shares, Inbank’s share capital after the registration of the share capital increase in the Estonian Commercial Register will be 1,086,415.40 euros and the total number of Inbank shares after the issue is 10,864,154. According to Priit Põldoja, CEO and Chairman of the Management Board of Inbank, the purpose of the issue was to strengthen Inbank capital structure in order to support continued...

Regenx Announces Closing of Convertible Debenture Offering

Written by Customer Service on November 2, 2023. Posted in Public Companies.

EDMONTON, Alberta, Nov. 02, 2023 (GLOBE NEWSWIRE) — Regenx Tech Corp., (the “Company” or “Regenx”) (CSE: RGX) (OTCQB: RGXTF) (FSE: YRS WKN:A2DSW3) has closed the previously announced financing for gross proceeds of $3,030,830. The closing of the offering is subject to all required regulatory approvals, including the acceptance of the Canadian Securities Exchange. The offering is a non-brokered private placement of unsecured convertible debentures (“Debentures”). The Debentures bear interest at the rate of fifteen percent (15%) per annum and will mature on July 1, 2025. The Debentures will be convertible at the holder’s option into common shares of the Company (“Common Share”) at a conversion price of: (i) $0.105 per Common Share until one (1) year from the closing date; and (ii) $0.15 per Common Share for...

Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition

Written by Customer Service on November 2, 2023. Posted in Public Companies.

MP0533 shows acceptable safety profile in first three dose cohorts (5 patients total, data cut-off July 20); reported adverse reactions are of Grade 1/2 and no dose-limiting toxicity observed to date Emerging evidence of antitumor activity observed in dose cohort three, with one responder noted Data from ASH abstract released today support clinical proof of concept of MP0533 as a novel tetra-specific T cell engager Expanded data from the first three cohorts and data from fourth cohort will be presented at the ASH Annual Meeting and ExpositionZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics,...

Ultimovacs Announces Completion of Patient Enrollment in Supplementary Study to INITIUM, UV1 Phase II Trial in Malignant Melanoma

Written by Customer Service on November 2, 2023. Posted in Public Companies.

The supplementary study to INITIUM is designed to provide in-depth data on the biological activity and mode of action of the vaccine-induced T cells, to support the next stages of developmentEnrollment of 21 patients with unresectable or metastatic malignant melanoma completedAll patients received UV1 vaccination as an add-on to the checkpoint inhibitors ipilimumab and nivolumabOslo, November 2, 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announced the completed recruitment of 21 patients in the exploratory single-arm study complementing the INITIUM trial. INITIUM (NCT04382664) is Ultimovacs’ randomized Phase II trial investigating its universal cancer vaccine UV1 in combination with the checkpoint inhibitors ipilimumab and...

2023 9 months and III quarter consolidated unaudited interim report

Written by Customer Service on November 2, 2023. Posted in Public Companies.

COMMENTARY FROM MANAGEMENT Q3 2023 revenue for Merko Ehitus was EUR 122 million and for the nine months was EUR 340 million. Net profit in Q3 was EUR 12.7 million and net profit for the nine months increased to EUR 32.1 million. Merko delivered 665 apartments and 22 commercial units to customers in the first nine months of 2023. According to the management of Merko Ehitus, the Q3 and nine-month results were supported by delivery of presold apartments to customers in newly completed apartment developments. The Merko group has inventory of apartments that are under construction and presold is significantly smaller than in the past few years due to the recession and the slump in the real estate market and this will exert a negative impact on the group’s results in coming years. The poor macroeconomic picture and general uncertainty did not...

Addex Announces Participation in the Bio-Europe 2023 Conference

Written by Customer Service on November 2, 2023. Posted in Public Companies.

Geneva, Switzerland, November 2, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, and Dr. Mikhail Kalinichev, Head of Translational Science, will be attending the Bio-Europe 2023 Conference (November 6 – 8, 2023) in Munich, Germany. A pre-recorded presentation, in which Mr. Dyer provides a corporate update and discusses recent developments at Addex, will be available for viewing on-demand by registered participants. Mr. Dyer and Dr. Kalinichev will be available for one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting, please contact IR@addexpharma.com. About Addex Therapeutics: Addex Therapeutics is a clinical-stage...

Year: 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals